For its fourth fiscal quarter (ending December 31), Avanos Medical Inc (NYSE: AVNS) has reported a -3696% decline in E.P.S. from $0.24 a year ago to $-8.63 in the current quarter. E.P.S. were $-8.40 for the latest four quarters through December 31 versus $-0.21 for the same period a year ago — an increase of 3900%.
Recent Price Action
Avanos Medical Inc (NYSE: AVNS) stock rose modestly by 0.4% on 2/26/25. The stock closed at $15.62. Moreover, trading volume in this advance was unusually high at 182% of normal. The stock has been weak relative to the market over the last nine months but has risen 0.6% during the last week.
Current PriceTarget Research Rating
Avanos Medical has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Avanos Medical has a good Appreciation Score of 84 but a poor Power Rating of 19, and the Neutral Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment